Effects of Lutein on Visual Function

NCT ID: NCT03113864

Last Updated: 2018-12-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-15

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized, double blind, placebo-controlled intervention trial on the ocular benefits and inflammatory markers improvements of taking FloraGLO Lutein for 9 months. The population of interest is middle-aged men and women who have low levels of carotenoids in their eyes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The participants will be given a brief explanation of the study and asked to sign an informed consent form. During the screening visit, pre-study parameters will be measured in order to assess the subjects' eligibility to participate.

These include:

1. Medical History
2. Vital signs, Height and weight and BMI calculation
3. Visual Parameters
4. Blood draw for clinical chemistry and hematological safety

Intervention Period:

At baseline visual parameters and a serum sample for analysis of inflammatory markers will be taken. Supplements will be dispensed. Study visits will then be conducted every 3 months. At these visits, subjects will have visual parameters, adverse events, study diary, vitals, a questionnaire evaluating health/diet/exercise/alcohol, product distribution and compliance checked. A final serum/plasma sample will be taken at the final visit for re-assessment of safety parameters and inflammatory markers.

Compliance check:

The number of tablets dispensed at baseline and returned, as well as all intake information from a subject diary. Per protocol population is defined apriori as \>80%.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Nutrition Poor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, Double-Blind, Placebo-Controlled, Parallel Intervention Trial
Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
All parties involved in the study are blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Will be identical looking to treatment

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Daily supplementation for 9 months

Lutein

10 mg of FloraGLO Lutein

Group Type EXPERIMENTAL

Lutein

Intervention Type DIETARY_SUPPLEMENT

Daily Supplementation for 9 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Daily supplementation for 9 months

Intervention Type DIETARY_SUPPLEMENT

Lutein

Daily Supplementation for 9 months

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women age 40-60 years
* Corrected Visual Acuity of 20/20 to 20/25
* MPOD 0.05- 0.30 OD units
* Must be able to give written informed consent in English
* BMI \< or = 30 kg/m2
* Subject is willing to maintain a habitual diet and physical activity patterns throughout the study period

Exclusion Criteria

* Use of carotenoid, fish oil, or n-3 fatty acid supplements (within 2 months of study start)
* Ocular pathologies
* History of active small bowel disease or resection
* Uncontrolled hypertension
* Diabetes mellitus
* Pancreatic disease
* Pregnancy (or planning to become pregnant) or lactation
* Diseases that interfere with fat absorption
* Medication or supplements that contain a significant level of carotenoids
* Medications that interfere with fat absorption
* Use of drugs suspected of interfering with metabolism of blood clotting
* Chronic alcohol intake
* Stroke, head injury with loss of consciousness or seizures
* Severe Amblyopia resulting in visual acuity worse than 0.4 MAR
* Subject is a heavy smoker (\> 1 pack/day)
* A regular consumer of lutein rich foods or lutein supplements
* A regular consumer of foods high in DHA intake or DHA supplements
* Subject has donated more than 300 mL of blood during the last three months prior to screening
Minimum Eligible Age

40 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

DSM Nutritional Products, Inc.

INDUSTRY

Sponsor Role collaborator

Kemin Foods LC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The University of Manchester

Manchester, United Kindgom, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

16-004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Lutein in Retinitis Pigmentosa
NCT00029289 COMPLETED PHASE1/PHASE2